Clinical trials: Zika
Anemia
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
To evaluate the safety and efficacy of red blood cells (RBCs) prepared with the INTERCEPT Blood System for Red Blood Cells Pathogen Reduction Treatment (PRT) in comparison to conventional RBCs in patients who require RBC…
- Trial name
- RedeS (NCT03037164)
- Testing
- INTERCEPT Blood System for Red Blood Cells, Conventional (Control)
- Where
- 16 sites in United States, Puerto Rico and 1 more
- Volunteers
- 692 people
- Sponsor
- Cerus Corporation
Malaria Fever, Zika
Xpert® Tropical Fever Test on GeneXpert® Edge X System
This is a multi-site, observational, cross-sectional clinical study that includes geographically diverse sites within and outside the United States.
- Conditions
- Malaria Fever, Zika, Dengue Fever, Leptospirosis
- Trial name
- NCT07520279
- Testing
- Xpert Tropical Fever test
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Cepheid
Zika, Zika Virus Infection
Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
This phase 1 clinical trial consists of an initial open-label sentinel run-in (n=25) and a randomized, double-blind, dose-finding (n=125) investigating three antigen dose levels (low, medium and high) of VLA1601 and bedside…
- Trial name
- NCT06334393
- Testing
- VLA1601, CpG 1018®, 3M-052-AF
- Where
- 4 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Zika Virus
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas
This clinical study will evaluate the safety, tolerability, and reactogenicity of 2 dose levels of messenger RNA (mRNA)-1893 Zika vaccine in comparison to a placebo control in healthy participants who are flavivirus-seronegative…
- Trial name
- NCT04917861
- Testing
- mRNA-1893
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 808 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Healthy
GLS-5700 in Dengue Virus-Naïve Adults
The clinical trial will assess the safety, tolerability, and immunogenicity of GLS-5700. GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus.
- Trial name
- NCT02809443
- Testing
- GLS-5700
- Where
- 3 sites in United States, Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
Zika Virus
Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects
The clinical study will assess the safety, tolerability, and immunogenicity of mRNA-1325 in healthy adult subjects.
- Trial name
- NCT03014089
- Testing
- mRNA-1325
- Where
- 3 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Zika Virus
Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults
This clinical study will evaluate the safety, tolerability and reactogenicity of mRNA-1893 Zika vaccines in flavivirus seronegative and flavivirus seropositive participants
- Trial name
- NCT04064905
- Testing
- mRNA-1893
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Arbovirus Infections, Dengue
Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia
Arboviruses, diseases transmitted to humans by the bite of an insect vector, are a major public health problem, especially in tropical and sub-tropical countries.
- Conditions
- Arbovirus Infections, Dengue, Zika, Chikungunya
- Trial name
- DENWOLUTION (NCT04615364)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Institut Pasteur
Arbovirus Infections, Zika
Virological and Immunological Determinants of Arbovirus Infection in New Caledonia
Arboviruses, diseases transmitted to humans by the bite of an insect vector, are a major public health problem, particularly in tropical and sub-tropical countries.
- Conditions
- Arbovirus Infections, Zika, Dengue, Chikungunya
- Trial name
- VIRIMA (NCT04619823)
- Testing
- Blood sample collection
- Where
- New Caledonia
- Volunteers
- 250 people
- Sponsor
- Institut Pasteur
Arbovirus Disease, Zika
Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu
The Pacific region is facing several emerging and neglected diseases notably mosquito-borne diseases as malaria or arboviroses among which dengue, Ross River, chikungunya and Zika.
- Conditions
- Arbovirus Disease, Zika, Dengue, Ross River
- Trial name
- PIANO (NCT05153018)
- Testing
- Blood collection
- Where
- 4 sites in Vanuatu
- Volunteers
- 1,122 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Zika Virus Infection, Zika Virus Disease
Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)
Currently, there are no licensed therapeutics against Zika virus infection. Due to this unmet medical need, Zika Virus Immune Globulin (ZIKV-IG) is being developed as a therapeutic intervention against Zika virus infection.
- Trial name
- NCT03624946
- Testing
- Zika Virus Immune Globulin (ZIKV-IG)
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Zika Virus
Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001)
Double blinded, randomized, placebo-controlled, dose finding, multi-center, phase 1 trial in 48 healthy volunteer subjects. After completion of screening procedures, the subjects are randomized to one of four treatment groups…
- Trial name
- NCT02996890
- Testing
- MV-ZIKA
- Where
- 2 sites in Austria
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Themis Bioscience GmbH
Zika Virus Disease
Zika Case Definition and Surveillance Study
This prospective, surveillance study will assess the operational Zika virus definition for use in future Zika purified inactivated virus (ZIKV) vaccine efficacy trials in order to identify Zika virus disease (ZVD) cases among the…
- Trial name
- NCT03158233
- Where
- 6 sites in Colombia, Honduras and 2 more
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Treatment of Acute Zika Virus Infection
Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in ZIKV Infected Patients
Zika virus (ZIKV) infection is a new emerging arbovirus disease, caused by the same vector that transmits Dengue virus, Aedes aegypti.
- Trial name
- NCT03776695
- Testing
- Tyzivumab
- Where
- Singapore
- Sponsor
- Tychan Pte Ltd.
Virus, Zika, Zika Virus Disease
Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants
The purpose of this study is to describe the safety, tolerability and immunogenicity of two doses of purified inactivated Zika virus vaccine (PIZV) given 28 days apart.
- Conditions
- Virus, Zika, Zika Virus Disease, Flavivirus Infections, Healthy Participants
- Trial name
- NCT03343626
- Testing
- PIZV
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 271 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy, Zika
GLS-5700 in Dengue Virus Seropositive Adults
The clinical trial will assess the safety, tolerability, and immunogenicity of GLS-5700. GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus.
- Trial name
- NCT02887482
- Testing
- GLS-5700
- Where
- 3 sites in Puerto Rico
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
Zika Virus Infection
Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001)
This study is designed to investigate, at first, safety and tolerability of a novel liquid vaccine formulation named MV-ZIKA-RSP, in healthy adults aged 18 to 55 years
- Trial name
- MV-ZIKA-RSP (NCT04033068)
- Testing
- Two MV-ZIKA-RSP vaccinations (high dose), Two MV-ZIKA-RSP vaccination (low dose)
- Where
- Austria
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Themis Bioscience GmbH
Zika Virus Infection
Safety and Immunogenicity of BBV121
To evaluate the safety, tolerability, and immunogenicity of two-doses of three-sequentially escalating cohort (2.5 µg, 5 µg and 10 µg) of BBV121 (purified inactivated adsorbed Zika virus vaccine) compared with Placebo (Alum).
- Trial name
- Zika (NCT04478656)
- Testing
- BBV121
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
Zika Virus, Zika Virus Infection
Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults
In this Phase 1 study, two target dose levels of VLA1601, a purified, inactivated, whole Zika virus (ZIKV) vaccine candidate adsorbed on aluminum hydroxide (alum) will be evaluated: 6 antigen units (AU) and 3 AU of inactivated…
- Trial name
- NCT03425149
- Testing
- VLA1601
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Treatment of Acute Zika Virus Infection
Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in Humans
Zika virus (ZIKV) infection is a new emerging arbovirus disease, caused by the same vector that transmits Dengue virus, Aedes aegypti.
- Trial name
- NCT03443830
- Testing
- Tyzivumab
- Where
- Singapore
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Tychan Pte Ltd.